EP3329909A1 — Fenfluramine for use in the treatment of dravet syndrome
Assigned to University Hospital Antwerp · Expires 2018-06-06 · 8y expired
What this patent protects
Fenfluramine or its pharmaceutically acceptable salt for use in a method of treating and / or preventing Dravet Syndrome in a patient, such as a patient previously diagnosed with Dravet Syndrome, wherein the method comprises administering an effective dose of fenfluramine or its …
USPTO Abstract
Fenfluramine or its pharmaceutically acceptable salt for use in a method of treating and / or preventing Dravet Syndrome in a patient, such as a patient previously diagnosed with Dravet Syndrome, wherein the method comprises administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.